Abstract
Calcific uremic arteriolopathy (CUA), also referred to as calciphylaxis, is a poorly understood syndrome of vascular calcification and cutaneous necrosis first described in 1898 when its presence was associated with uremia. At present, it is believed to be caused by arteriolar calcification and cutaneous plaque formation which causes vascular stenosis which predisposes to thrombotic occlusion causing tissue ischemia and violaceous skin lesions that may progress to nonhealing ulceration and gangrene which may lead to amputation, sepsis, and death. Although there are many reports of calciphylaxis associated with nonuremic causes, the majority of cases occur in patients with end-stage renal disease on dialysis. It is likely that uremia creates a favorable milieu for extraskeletal deposition of hydroxyapatite in soft tissues including small vessels, predisposing to thrombus formation, and the development of calciphylaxis. In this chapter, the authors present a discussion of the basic and clinical aspects of the disease process as well as novel therapeutic options.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- 25-(OH)D3 :
-
25-Hydroxyvitamin D3 (also known as: 25-hydroxycholecalciferol, calcifediol, or calcidiol)
- 1,25-(OH2)D3 :
-
1,25-Dihydroxyvitamin D3 (also known as: 1,25-dihydroxycholecalciferol or calcitriol)
- ApoE:
-
Apolipoprotein E
- BMP:
-
Bone morphogenic protein
- CKD:
-
Chronic kidney disease
- CKD-MBD:
-
Chronic kidney disease-mineral and bone disorder (also known as: renal osteodystrophy)
- EGFRs:
-
Epidermal growth factor receptors
- ESRD:
-
End-stage renal disease
- FGF-23:
-
Fibroblast growth factor-23
- HPT:
-
Hyperparathyroidism
- IL-1, IL-6:
-
Interleukin-1 and -6
- LDL:
-
Low-density lipoprotein
- MGP:
-
Matrix Gla protein
- OPG:
-
Osteoprotegerin
- OPN:
-
Osteopontin
- PTH:
-
Parathyroid hormone (also known as: parathormone or parathyrin)
- TGF-α:
-
Transforming growth factor-alpha
- TGF-β:
-
Transforming growth factor-beta
- TNF-α:
-
Tumor necrosis factor-alpha
- ucMGP:
-
Uncarboxylated matrix Gla protein
References
Selye H. Calciphylaxis. Chicago: University of Chicago Press; 1962.
Selye H, Gabbiani G, Strebel R. Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinology. 1962;71:554–8.
Gipstein RM, Coburn JW, Adams DA, et al. Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med. 1976;136:1273–80.
Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol. 2008;58:458–71.
Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis. 1998;32:384–91.
Janigan DT, Hirsch DJ, Klassen GA, et al. Calcified subcutaneous arterioles with infarcts of the subcutis and skin (“calciphylaxis”) in chronic renal failure. Am J Kidney Dis. 2000;35:588–97.
Anderson DC, Stewart WK, Piercy DM. Calcifying panniculitis with fat and skin necrosis in a case of uraemia with autonomous hyperparathyroidism. Lancet. 1968;2:323–5.
Carlson JA, Chen KR. Cutaneous pseudovasculitis. Am J Dermatopathol. 2007;29:44–55.
Conn Jr J, Krumlovsky FA, Del Greco F, et al. Calciphylaxis: etiology of progressive vascular calcification and gangrene? Ann Surg. 1973;177:206–10.
Dahl PR, Winkelmann RK, Connolly SM. The vascular calcification-cutaneous necrosis syndrome. J Am Acad Dermatol. 1995;33:53–8.
Friedman SA, Novack S, Thomson GE. Arterial calcification and gangrene in uremia. N Engl J Med. 1969;280:1392–4.
Grob JJ, Legre R, Bertocchio P, et al. Calcifying panniculitis and kidney failure. Considerations on pathogenesis and treatment of calciphylaxis. Int J Dermatol. 1989;28:129–31.
Hafner J, Keusch G, Wahl C, et al. Calciphylaxis: a syndrome of skin necrosis and acral gangrene in chronic renal failure. Vasa. 1998;27:137–43.
Henschel A, Dannenberg L, Gobel U, et al. Disseminated ischemic necrosis and livedo racemosa in a chronic dialysis patient with calciphylaxis. Hautarzt. 1999;50:439–44.
Kane WJ, Petty PM, Sterioff S, et al. The uremic gangrene syndrome: improved healing in spontaneously forming wounds following subtotal parathyroidectomy. Plast Reconstr Surg. 1996;98:671–8.
Kyttaris VC, Timbil S, Kalliabakos D, et al. Calciphylaxis: a pseudo-vasculitis syndrome. Semin Arthritis Rheum. 2007;36:264–7.
Levin A, Mehta RL, Goldstein MB. Mathematical formulation to help identify the patient at risk of ischemic tissue necrosis—a potentially lethal complication of chronic renal failure. Am J Nephrol. 1993;13:448–53.
Llach F. Calcific uremic arteriolopathy (calciphylaxis): an evolving entity? Am J Kidney Dis. 1998;32:514–8.
Lowry LR, Tschen JA, Wolf JE, et al. Calcifying panniculitis and systemic calciphylaxis in an end-stage renal patient. Cutis. 1993;51:245–7.
Peterson R. Small vessel calcification and its relationship to secondary hyperparathyroidism in the renal homotransplant patient. Radiology. 1978;126:627–33.
Rogers NM, Teubner DJ, Coates PT. Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dial. 2007;20:150–7.
Ross CN, Cassidy MJ, Thompson M, et al. Proximal cutaneous necrosis associated with small vessel calcification in renal failure. Q J Med. 1991;79:443–50.
Stout C, Ayoub M. Calcific uremic arteriolopathy. Hosp Physician. 2007;43(1):31–7.
Korber A, Klode J, Al-Benna S, et al. Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey. J Dtsch Dermatol Ges. 2011;9(2):116–21.
Angelis M, Wong LL, Myers SA, et al. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122:1083–9. discussion 1089–90.
Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol. 1996;7:978–82.
Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60:324–32.
Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61:2210–7.
Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15:2959–64.
Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int Suppl. 2002;62:S73–80.
Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15:218–23.
Contiguglia SR, Alfrey AC, Miller NL, et al. Nature of soft tissue calcification in uremia. Kidney Int. 1973;4:229–35.
Speer MY, Giachelli CM. Regulation of cardiovascular calcification. Cardiovasc Pathol. 2004;13:63–70.
Llach F. The evolving pattern of calciphylaxis: therapeutic considerations. Nephrol Dial Transplant. 2001;16:448–51.
Llach F. The evolving clinical features of calciphylaxis. Kidney Int Suppl. 2003:S122–4.
Fraser WD. Hyperparathyroidism. Lancet. 2009;374:145–58.
Cottone S, Lorito MC, Riccobene R, et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J Nephrol. 2008;21:175–9.
Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004;15 Suppl 1:S77–80.
Covic A, Kanbay M, Voroneanu L, et al. Vascular calcification in chronic kidney disease. Clin Sci (Lond). 2010;119:111–21.
Spasovski G, Massy Z, Vanholder R. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Semin Dial. 2009;22:357–62.
Sowers KM, Hayden MR. Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev. 2010;3:109–21.
Tintut Y, Patel J, Territo M, et al. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002;105:650–5.
Collin-Osdoby P, Rothe L, Anderson F, et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 2001;276:20659–72.
Kaden JJ, Bickelhaupt S, Grobholz R, et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol. 2004;36:57–66.
Schoppet M, Al-Fakhri N, Franke FE, et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg’s sclerosis and atherosclerosis. J Clin Endocrinol Metab. 2004;89:4104–12.
Tintut Y, Abedin M, Cho J, et al. Regulation of RANKL-induced osteoclastic differentiation by vascular cells. J Mol Cell Cardiol. 2005;39:389–93.
Jules J, Ashley JW, Feng X. Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. Expert Opin Ther Targets. 2010;14:923–34.
Enjuanes A, Ruiz-Gaspa S, Peris P, et al. The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts. Endocrine. 2010;37:180–6.
Giner M, Rios MJ, Montoya MJ, et al. Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis. Eur J Pharmacol. 2011;650(2–3):682–7.
Koch FP, Merkel C, Ziebart T, et al. Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Investig. 2012;16(1):79–86.
Neville-Webbe HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer. 2010;46:1211–22.
Munroe PB, Olgunturk RO, Fryns JP, et al. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet. 1999;21:142–4.
Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81.
Cancela L, Hsieh CL, Francke U, et al. Molecular structure, chromosome assignment, and promoter organization of the human matrix Gla protein gene. J Biol Chem. 1990;265:15040–8.
Wallin R, Cain D, Sane DC. Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells—a cell system which resembles the system in bone cells. Thromb Haemost. 1999;82:1764–7.
Schurgers LJ, Barreto DV, Barreto FC, et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol. 2010;5:568–75.
Cranenburg EC, Vermeer C, Koos R, et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res. 2008;45:427–36.
Jahnen-Dechent W, Schafer C, Ketteler M, et al. Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. J Mol Med. 2008;86:379–89.
Shroff RC, Shanahan CM. The vascular biology of calcification. Semin Dial. 2007;20:103–9.
Suliman ME, Garcia-Lopez E, Anderstam B, et al. Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. Adv Clin Chem. 2008;46:217–62.
Blaha V, Mistrik E, Dusilova-Sulkova S, et al. Circulating fetuin-A predicts early mortality in chronic hemodialysis patients. Clin Biochem. 2009;42:996–1000.
Hermans MM, Brandenburg V, Ketteler M, et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007;72:202–7.
Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827–33.
Verduijn M, Prein RA, Stenvinkel P, et al. Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker? A Mendelian randomization approach. Nephrol Dial Transplant. 2011;26(1):239–45.
Cozzolino M, Galassi A, Biondi ML, et al. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol. 2006;26:423–9.
Cozzolino M, Gallieni M, Brancaccio D. Inflammation and vascular calcification in chronic kidney disease: the role of Fetuin-A. Cytokine. 2009;45:70–1.
Wang AY, Lam CW, Chan IH, et al. Long-term mortality and cardiovascular risk stratification of peritoneal dialysis patients using a combination of inflammation and calcification markers. Nephrol Dial Transplant. 2009;24:3826–33.
Wang AY, Lam CW, Wang M, et al. Increased circulating inflammatory proteins predict a worse prognosis with valvular calcification in end-stage renal disease: a prospective cohort study. Am J Nephrol. 2008;28:647–53.
Westenfeld R, Schafer C, Smeets R, et al. Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant. 2007;22:1537–46.
Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112:357–66.
Rittenberg B, Partridge E, Baker G, et al. Regulation of BMP-induced ectopic bone formation by Ahsg. J Orthop Res. 2005;23:653–62.
Westenfeld R, Schafer C, Kruger T, et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol. 2009;20:1264–74.
Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab. 2008;93:4479–85.
Yilmaz Y, Yonal O, Kurt R, et al. Serum fetuin A/{alpha}2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann Clin Biochem. 2010;47(Pt 6):549–53.
Reddi AH, Reddi A. Bone morphogenetic proteins (BMPs): from morphogens to metabologens. Cytokine Growth Factor Rev. 2009;20:341–2.
McCullough PA, Chinnaiyan KM, Agrawal V, et al. Amplification of atherosclerotic calcification and Monckeberg’s sclerosis: a spectrum of the same disease process. Adv Chronic Kidney Dis. 2008;15:396–412.
Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol. 2003;14:1559–67.
Moe SM, O’Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002;61:638–47.
Griethe W, Schmitt R, Jurgensen JS, et al. Bone morphogenic protein-4 expression in vascular lesions of calciphylaxis. J Nephrol. 2003;16:728–32.
Csiszar A, Smith KE, Koller A, et al. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation. 2005;111:2364–72.
Feng JQ, Xing L, Zhang JH, et al. NF-kappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol Chem. 2003;278:29130–5.
Ducy P, Starbuck M, Priemel M, et al. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 1999;13:1025–36.
Engelse MA, Neele JM, Bronckers AL, et al. Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor alpha-1 and the protective factor matrix gla protein in human atherogenesis. Cardiovasc Res. 2001;52:281–9.
Karsenty G, Ducy P, Starbuck M, et al. Cbfa1 as a regulator of osteoblast differentiation and function. Bone. 1999;25:107–8.
Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89:755–64.
Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89:1147–54.
Schroeder TM, Jensen ED, Westendorf JJ. Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today. 2005;75:213–25.
Waller AH, Sanchez-Ross M, Kaluski E, et al. Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiol Rev. 2010;18:125–31.
Jono S, Shioi A, Ikari Y, et al. Vascular calcification in chronic kidney disease. J Bone Miner Metab. 2006;24:176–81.
Rennenberg RJ, Schurgers LJ, Kroon AA, et al. Arterial calcifications. J Cell Mol Med. 2010;14:2203–10.
Ikeda T, Shirasawa T, Esaki Y, et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest. 1993;92:2814–20.
Reinholt FP, Hultenby K, Oldberg A, et al. Osteopontin—a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA. 1990;87:4473–5.
Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89:747–54.
Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol. 2004;26:179–84.
Merry K, Dodds R, Littlewood A, et al. Expression of osteopontin mRNA by osteoclasts and osteoblasts in modelling adult human bone. J Cell Sci. 1993;104(Pt 4):1013–20.
Fatherazi S, Matsa-Dunn D, Foster BL, et al. Phosphate regulates osteopontin gene transcription. J Dent Res. 2009;88:39–44.
Ahmed S, O’Neill KD, Hood AF, et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis. 2001;37:1267–76.
Shao JS, Cheng SL, Sadhu J, et al. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension. 2010;55:579–92.
Stinghen AE, Bucharles S, Riella MC, et al. Immune mechanisms involved in cardiovascular complications of chronic kidney disease. Blood Purif. 2010;29:114–20.
Tintut Y, Patel J, Parhami F, et al. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation. 2000;102:2636–42.
Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95:560–7.
El-Abbadi MM, Pai AS, Leaf EM, et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009;75:1297–307.
Arch-Ferrer JE, Beenken SW, Rue LW, et al. Therapy for calciphylaxis: an outcome analysis. Surgery. 2003;134:941–4. discussion 944–5.
Awwad ST, Ghosn S, Hogan RN. Calciphylaxis of the temporal artery masquerading as temporal arteritis. Clin Experiment Ophthalmol. 2010;38:511–3.
Bedoya RM, Gutierrez JL, Mayorga F. Calciphylaxis causing localized tongue necrosis: a case report. J Oral Maxillofac Surg. 1997;55:193–6.
Crippa C, Ferrari S, Drera M, et al. Pulmonary calciphylaxis and metastatic calcification with acute respiratory failure in multiple myeloma. J Clin Oncol. 2010;28:e133–5.
Giacobetti R, Feldman SA, Ivanovich P, et al. Sudden fatal pulmonary calcification following renal transplantation. Nephron. 1977;19:295–300.
Khafif RA, Delima C, Silverberg A, et al. Acute hyperparathyroidism with systemic calcinosis. Report of a case. Arch Intern Med. 1989;149:681–4.
Schmidt H, Creutzfeldt W. Calciphylactic pancreatitis and pancreatitis in hyperparathyroidism. Clin Orthop Relat Res. 1970;69:135–45.
Shapiro C, Coco M. Gastric calciphylaxis in a patient with a functioning renal allograft. Clin Nephrol. 2007;67:119–25.
Tuthill MH, Stratton J, Warrens AN. Calcific uremic arteriolopathy presenting with small and large bowel involvement. J Nephrol. 2006;19:115–8.
Brouns K, Verbeken E, Degreef H, et al. Fatal calciphylaxis in two patients with giant cell arteritis. Clin Rheumatol. 2007;26:836–40.
Wilmer WA, Voroshilova O, Singh I, et al. Transcutaneous oxygen tension in patients with calciphylaxis. Am J Kidney Dis. 2001;37:797–806.
D’Agata EM, Mount DB, Thayer V, et al. Hospital-acquired infections among chronic hemodialysis patients. Am J Kidney Dis. 2000;35:1083–8.
Johnson LB, Venugopal AA, Pawlak J, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal disease. Infect Control Hosp Epidemiol. 2006;27:1057–62.
Pop-Vicas A, Strom J, Stanley K, et al. Multidrug-resistant gram-negative bacteria among patients who require chronic hemodialysis. Clin J Am Soc Nephrol. 2008;3:752–8.
Bleyer AJ, Choi M, Igwemezie B, et al. A case control study of proximal calciphylaxis. Am J Kidney Dis. 1998;32:376–83.
Fine A, Fontaine B. Calciphylaxis: the beginning of the end? Perit Dial Int. 2008;28:268–70.
Alikadic N, Kovac D, Krasna M, et al. Review of calciphylaxis and treatment of a severe case after kidney transplantation with iloprost in combination with hyperbaric oxygen and cultured autologous fibrin-based skin substitutes. Clin Transplant. 2009;23:968–74.
Brewster UC, Perazella MA. Calcific uremic arteriolopathy in a transplanted kidney. Am J Med Sci. 2005;329:102–3.
Hanvesakul R, Silva MA, Hejmadi R, et al. Calciphylaxis following kidney transplantation: a case report. J Med Case Reports. 2009;3:9297.
Massry SG, Gordon A, Coburn JW, et al. Vascular calcification and peripheral necrosis in a renal transplant recipient. Reversal of lesions following subtotal parathyroidectomy. Am J Med. 1970;49:416–22.
Wenzel-Seifert K, Harwig S, Keller F. Fulminant calcinosis in two patients after kidney transplantation. Am J Nephrol. 1991;11:497–500.
Hafner J, Keusch G, Wahl C, et al. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol. 1995;33:954–62.
Chan YL, Mahony JF, Turner JJ, et al. The vascular lesions associated with skin necrosis in renal disease. Br J Dermatol. 1983;109:85–95.
Kang AS, McCarthy JT, Rowland C, et al. Is calciphylaxis best treated surgically or medically? Surgery. 2000;128:967–71. discussion 971–2.
Zacharias JM, Fontaine B, Fine A. Calcium use increases risk of calciphylaxis: a case-control study. Perit Dial Int. 1999;19:248–52.
Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56:569–79.
Ruggian JC, Maesaka JK, Fishbane S. Proximal calciphylaxis in four insulin-requiring diabetic hemodialysis patients. Am J Kidney Dis. 1996;28:409–14.
Caetano-Lopes J, Canhao H, Fonseca JE. Osteoblasts and bone formation. Acta Reumatol Port. 2007;32:103–10.
Lamghari M, Tavares L, Camboa N, et al. Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts. J Cell Biochem. 2006;98:1123–9.
Campistol JM, Almirall J, Martin E, et al. Calcium-carbonate-induced calciphylaxis. Nephron. 1989;51:549–50.
Block GA. Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol. 2000;54:318–24.
Morales E, Gutierrez E, Andres A. Treatment with calcimimetics in kidney transplantation. Transplant Rev (Orlando). 2010;24:79–88.
Plantinga LC, Fink NE, Melamed ML, et al. Serum phosphate levels and risk of infection in incident dialysis patients. Clin J Am Soc Nephrol. 2008;3:1398–406.
Powe NR, Jaar B, Furth SL, et al. Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int. 1999;55:1081–90.
Torok L, Kozepessy L. Cutaneous gangrene due to hyperparathyroidism secondary to chronic renal failure (uraemic gangrene syndrome). Clin Exp Dermatol. 1996;21:75–7.
Nigwekar SU, Wolf M, Sterns RH, et al. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008;3:1139–43.
Duh QY, Lim RC, Clark OH. Calciphylaxis in secondary hyperparathyroidism. Diagnosis and parathyroidectomy. Arch Surg. 1991;126:1213–8. discussion 1218–9.
Mawad HW, Sawaya BP, Sarin R, et al. Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol. 1999;52:160–6.
Smith AJ, Faugere MC, Abreo K, et al. Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol. 1986;6:275–83.
Kasai K, Hori MT, Goodman WG. Transferrin enhances the antiproliferative effect of aluminum on osteoblast-like cells. Am J Physiol. 1991;260:E537–43.
Bishop J, Brown E, Podesta A, et al. Surgical management of calciphylaxis associated with primary hyperparathyroidism: a case report and review of the literature. Int J Endocrinol. 2010; 2010. pii 823210.
Girotto JA, Harmon JW, Ratner LE, et al. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery. 2001;130: 645–50. discussion 650–1.
Zechlinski JJ, Angel JR. Calciphylaxis in the absence of renal disease: secondary hyperparathyroidism and systemic lupus erythematosus. J Rheumatol. 2009;36:2370–1.
Harris RJ, Cropley TG. Possible role of hypercoagulability in calciphylaxis: review of the literature. J Am Acad Dermatol. 2011;64(2):405–12.
Kant KS, Glueck HI, Coots MC, et al. Protein S deficiency and skin necrosis associated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1992;19:264–71.
Mehta RL, Scott G, Sloand JA, et al. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med. 1990;88:252–7.
Perez-Mijares R, Guzman-Zamudio JL, Payan-Lopez J, et al. Calciphylaxis in a haemodialysis patient: functional protein S deficiency? Nephrol Dial Transplant. 1996;11:1856–9.
Sankarasubbaiyan S, Scott G, Holley JL. Cryofibrinogenemia: an addition to the differential diagnosis of calciphylaxis in end-stage renal disease. Am J Kidney Dis. 1998;32:494–8.
Wong JJ, Laumann A, Martinez M. Calciphylaxis and antiphospholipid antibody syndrome. J Am Acad Dermatol. 2000;42:849.
Ozbalkan Z, Calguneri M, Onat AM, et al. Development of calciphylaxis after long-term steroid and methotroxate use in a patient with rheumatoid arthritis. Intern Med. 2005;44:1178–81.
Korkmaz C, Dundar E, Zubaroglu I. Calciphylaxis in a patient with rheumatoid arthritis without renal failure and hyperparathyroidism: the possible role of long-term steroid use and protein S deficiency. Clin Rheumatol. 2002;21:66–9.
Barri YM, Graves GS, Knochel JP. Calciphylaxis in a patient with Crohn’s disease in the absence of end-stage renal disease. Am J Kidney Dis. 1997;29:773–6.
Al Beladi FI. Catastrophic calciphylaxis in a patient with lupus nephritis and recent onset of end-stage renal disease. Saudi J Kidney Dis Transpl. 2010;21:323–7.
Lee JL, Naguwa SM, Cheema G, et al. Recognizing calcific uremic arteriolopathy in autoimmune disease: an emerging mimicker of vasculitis. Autoimmun Rev. 2008;7:638–43.
Ortiz A, Ceccato F, Roverano S, et al. Calciphylaxis associated with rheumatoid arthritis: communication of the second case. Clin Rheumatol. 2009;28 Suppl 1:S65–8.
Slough S, Servilla KS, Harford AM, et al. Association between calciphylaxis and inflammation in two patients on chronic dialysis. Adv Perit Dial. 2006;22:171–4.
Swanson AM, Desai SR, Jackson JD, et al. Calciphylaxis associated with chronic inflammatory conditions, immunosuppression therapy, and normal renal function: a report of 2 cases. Arch Dermatol. 2009;145:723–5.
De Roma I, Filotico R, Cea M, et al. Calciphylaxis in a patient with POEMS syndrome without renal failure and/or hyperparathyroidism. A case report. Ann Ital Med Int. 2004;19:283–7.
Hineno A, Kinoshita T, Kinoshita M, et al. Calciphylaxis as a catastrophic complication in a patient with POEMS syndrome. Case Rep Neurol. 2009;1:47–53.
Lee FY, Chiu HC. POEMS syndrome with calciphylaxis: a case report. Acta Derm Venereol. 2011;91(1):96–7.
Rossi D, Gaidano G. POEMS and calciphylaxis: a novel association? Ann Ital Med Int. 2004;19:235–7.
Yoshikawa M, Uhara H, Arakura F, et al. Calciphylaxis in POEMS syndrome: a case treated with etidronate. Acta Derm Venereol. 2011;91(1):98–9.
Fader DJ, Kang S. Calciphylaxis without renal failure. Arch Dermatol. 1996;132:837–8.
Ferreres JR, Marcoval J, Bordas X, et al. Calciphylaxis associated with alcoholic cirrhosis. J Eur Acad Dermatol Venereol. 2006;20:599–601.
Lim SP, Batta K, Tan BB. Calciphylaxis in a patient with alcoholic liver disease in the absence of renal failure. Clin Exp Dermatol. 2003;28:34–6.
Banerjee C, Woller SC, Holm JR, et al. Atypical calciphylaxis in a patient receiving warfarin then resolving with cessation of warfarin and application of hyperbaric oxygen therapy. Clin Appl Thromb Hemost. 2010;16:345–50.
Comp PC, Elrod JP, Karzenski S. Warfarin-induced skin necrosis. Semin Thromb Hemost. 1990;16:293–8.
Chacon G, Nguyen T, Khan A, et al. Warfarin-induced skin necrosis mimicking calciphylaxis: a case report and review of the literature. J Drugs Dermatol. 2010;9:859–63.
Jacobs-Kosmin D, Dehoratius RJ. Calciphylaxis: an important imitator of cutaneous vasculitis. Arthritis Rheum. 2007;57:533–7.
Wallace JS, Hall JC. Use of drug therapy to manage acute cutaneous necrosis of the skin. J Drugs Dermatol. 2010;9:341–9.
Cicone JS, Petronis JB, Embert CD, et al. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004;43:1104–8.
Landau D, Krymko H, Shalev H, et al. Transient severe metastatic calcification in acute renal failure. Pediatr Nephrol. 2007;22:607–11.
Soni S, Leslie WD. Bone scan findings in metastatic calcification from calciphylaxis. Clin Nucl Med. 2008;33:502–4.
Bleibel W, Hazar B, Herman R. A case report comparing various radiological tests in the diagnosis of calcific uremic arteriolopathy. Am J Kidney Dis. 2006;48:659–61.
Don BR, Chin AI. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol. 2003;59:463–70.
Barginear MF, Donahue L, Allen SL, et al. Heparin-induced thrombocytopenia complicating hemodialysis. Clin Appl Thromb Hemost. 2008;14: 105–7.
Chan MR, Yevzlin AS, Hinshaw M, et al. Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy. WMJ. 2008;107:335–8.
Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1:697–703.
Goldberg DI, Dillon MA, Slatopolsky EA, et al. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant. 1998;13:2303–10.
Oikawa S, Osajima A, Tamura M, et al. Development of proximal calciphylaxis with penile involvement after parathyroidectomy in a patient on hemodialysis. Intern Med. 2004;43:63–8.
Wang HY, Yu CC, Huang CC. Successful treatment of severe calciphylaxis in a hemodialysis patient using low-calcium dialysate and medical parathyroidectomy: case report and literature review. Ren Fail. 2004;26:77–82.
Stracke S, Keller F, Steinbach G, et al. Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism. Nephron Clin Pract. 2009;111:c102–9.
Mohammed IA, Sekar V, Bubtana AJ, et al. Proximal calciphylaxis treated with calcimimetic ‘Cinacalcet’. Nephrol Dial Transplant. 2008;23:387–9.
Pallure V, Comte C, Leray-Mouragues H, et al. Cinacalcet as first-line treatment for calciphylaxis. Acta Derm Venereol. 2008;88:62–3.
Robinson MR, Augustine JJ, Korman NJ. Cinacalcet for the treatment of calciphylaxis. Arch Dermatol. 2007;143:152–4.
Velasco N, MacGregor MS, Innes A, et al. Successful treatment of calciphylaxis with cinacalcet—an alternative to parathyroidectomy? Nephrol Dial Transplant. 2006;21:1999–2004.
Drueke TB, Ritz E. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol. 2009;4:234–41.
Dickey DT, Wu YJ, Muldoon LL, et al. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005;314:1052–8.
Hall AH, Dart R, Bogdan G. Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning? Ann Emerg Med. 2007;49: 806–13.
Pasch A, Schaffner T, Huynh-Do U, et al. Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int. 2008;74:1444–53.
Kyriakopoulos G, Kontogianni K. Sodium thiosulfate treatment of tumoral calcinosis in patients with end-stage renal disease. Ren Fail. 1990;12:213–9.
Papadakis JT, Patrikarea A, Digenis GE, et al. Sodium thiosulfate in the treatment of tumoral calcifications in a hemodialysis patient without hyperparathyroidism. Nephron. 1996;72:308–12.
Yatzidis H, Agroyannis B. Sodium thiosulfate treatment of soft-tissue calcifications in patients with end-stage renal disease. Peritoneal Dial Bull. 1987;7:250–2.
Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant. 2005;20:1260–2.
Hayden MR, Goldsmith D, Sowers JR, et al. Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol. 2008;40:443–51.
Meissner M, Bauer R, Beier C, et al. Sodium thiosulphate as a promising therapeutic option to treat calciphylaxis. Dermatology. 2006;212:373–6.
Meissner M, Kaufmann R, Gille J. Sodium thiosulphate: a new way of treatment for calciphylaxis? Dermatology. 2007;214:278–82.
Raymond CB, Wazny LD. Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis. Am J Health Syst Pharm. 2008;65: 1419–29.
Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens. 2008;17:629–34.
Schlieper G, Brandenburg V, Ketteler M, et al. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol. 2009;5: 539–43.
Heller HJ, Zerwekh JE, Gottschalk FA, et al. Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int. 2007;71:808–15.
Agroyannis B, Tzanatos H, Vlahakos DV, et al. Does long-term administration of sodium thiosulphate inhibit progression to renal failure in nephrocalcinosis? Nephrol Dial Transplant. 2001;16:2443–4.
Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol. 1985;23:63–7.
Yatzidis H. Absence or decreased endogenous thiosulfaturia: a cause of recurrent calcium nephrolithiasis. Int Urol Nephrol. 2004;36:587–9.
da Costa JB, da Costa AG, Gomes MM. Pamidronate as a treatment option in calciphylaxis. J Eur Acad Dermatol Venereol. 2008;22:1128–30.
Monney P, Nguyen QV, Perroud H, et al. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant. 2004;19:2130–2.
Schliep S, Schuler G, Kiesewetter F. Successful treatment of calciphylaxis with pamidronate. Eur J Dermatol. 2008;18:554–6.
Shiraishi N, Kitamura K, Miyoshi T, et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis. 2006;48:151–4.
Musso CG, Enz PA, Guelman R, et al. Non-ulcerating calcific uremic arteriolopathy skin lesion treated successfully with intravenous ibandronate. Perit Dial Int. 2006;26:717–8.
Price PA, Omid N, Than TN, et al. The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int. 2002;71:356–63.
Sewell LD, Weenig RH, Davis MD, et al. Low-dose tissue plasminogen activator for calciphylaxis. Arch Dermatol. 2004;140:1045–8.
Mureebe L, Moy M, Balfour E, et al. Calciphylaxis: a poor prognostic indicator for limb salvage. J Vasc Surg. 2001;33:1275–9.
Bronson N, Menon R, Butler J, et al. Parathyroidectomy, excision and skin grafting with topical negative pressure for calciphylactic ulcers. J Wound Care. 2007;16:295–7.
Arenas MD, Gil MT, Gutierrez MD, et al. Management of calcific uremic arteriolopathy (calciphylaxis) with a combination of treatments, including hyperbaric oxygen therapy. Clin Nephrol. 2008;70:261–4.
Basile C. Hyperbaric oxygen therapy in the treatment of calciphylaxis? Yes, more than hope. Kidney Int. 2002;62:2300. author reply 2300.
Basile C, Montanaro A, Masi M, et al. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol. 2002;15:676–80.
Podymow T, Wherrett C, Burns KD. Hyperbaric oxygen in the treatment of calciphylaxis: a case series. Nephrol Dial Transplant. 2001;16: 2176–80.
Vassa N, Twardowski ZJ, Campbell J. Hyperbaric oxygen therapy in calciphylaxis-induced skin necrosis in a peritoneal dialysis patient. Am J Kidney Dis. 1994;23:878–81.
Dean SM, Werman H. Calciphylaxis: a favorable outcome with hyperbaric oxygen. Vasc Med. 1998;3:115–20.
Bishop A. Role of oxygen in wound healing. J Wound Care. 2008;17:399–402.
Wu SC, Marston W, Armstrong DG. Wound care: the role of advanced wound healing technologies. J Vasc Surg. 2010;52:59S–66.
Green JA, Green CR, Minott SD. Calciphylaxis treated with neurolytic lumbar sympathetic block: case report and review of the literature. Reg Anesth Pain Med. 2000;25:310–2.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Rudolph, E.H., Lerma, E.V. (2012). Calcific Uremic Arteriolopathy (Calciphylaxis). In: Licata, A., Lerma, E. (eds) Diseases of the Parathyroid Glands. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5550-0_6
Download citation
DOI: https://doi.org/10.1007/978-1-4419-5550-0_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-5549-4
Online ISBN: 978-1-4419-5550-0
eBook Packages: MedicineMedicine (R0)